BioTissue Technologies AG
BioTissue AG english
Expected sales 2002: Euro 2.1 million
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
– Expected sales of Euro 2.1 million for 2002, International marketing strategy
BioTissue Technologies AG (SIN 618061), the specialist for innovative tissue-
engineering-products, expects to book sales of Euro 2.1 million in financial
2002. This signifies a steady increase in sales revenues during the course of
the entire business year. Sales are thus 80 percent above those for the prior
year, but just under 30 percent below the target figure. As regards EBIT,
BioTissue expects to close 2002 with a loss of Euro -5.9 million as opposed to
the targeted loss of Euro -5.2 million. The difference here stems primarily from
the contribution to profits that failed to materialize owing to the shortfall
in sales.In terms of the market penetration and the necessary number of
practitioners already using our products, the company performed in line with
plans. During the year, practitioners have made their own favorable experiences
when treating patients with BioTissue products and this means that with
immediate effect the newly-launched products will increasingly be used
routinely. This will be reflected in sales in 2003. BioTissue has resolved an
international marketing concept for its new products. An exclusive distribution
agreement for Europe for one BioTissue product will be concluded with a partner
who is a world leader in the orthopedics segment. This alliance will, in a first
step, cover Germany, Austria, Italy and Switzerland; it will subsequently be
expanded to include the other European countries. The parameters have already
been agreed and signature of the relevant contract is expected for first-quarter
2003. Moreover, BioTissue has signed a cooperation contract with a leading
international provider of prosthetic implants covering a joint project to
develop a three-dimensional bone consisting of calcium phosphate and patient
owned bone cells. In this way, BioTissue has shored up its position in the
lucrative markets for traumatology and orthopedics. Following a capital increase
in November 2002, the company is currently preparing to take up additional
financial resources in first-half 2003.
Contact: BioTissue Technologies AG, Dr. Victor Tiegermann, CEO, Tel. +49 (0) 761
76 76-112, Fax +49 (0) 761 76 76-154, ir@biotissue-tec.com
end of ad-hoc-announcement (c)DGAP 23.12.2002
——————————————————————————–
WKN: 618061; ISIN: DE0006180615; Index:
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
230839 Dez 02
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden